Ferroptosis, type of cell death, may be therapeutic target for MASLD
A type of cell death called ferroptosis contributes to metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease that occurs more…
Fatty liver disease
Targeting SEMA3A protein could help slow MASLD: Study
A protein called semaphorin-3A (SEMA3A) may be a key player in the early cellular mechanisms that cause fat to accumulate in the livers of people…
Blood levels of GDF15 protein may help in liver cancer risk of MASLD
High blood levels of the growth differentiation factor 15 (GDF15) protein are associated with an elevated risk of liver cancer and other liver-related complications among…
Global Fatty Liver Day to raise awareness of ‘concealed epidemic’
Global Fatty Liver Day, this year falling on June 13, is an annual effort to raise awareness about metabolic dysfunction-associated steatotic liver disease…
In NASH, VK2809 treatment reduces liver fat, fibrosis: Phase 2b trial
One year of treatment with Viking Therapeutics’ candidate VK2809 safely and effectively reduces liver fat content, damage, and scarring in adults with nonalcoholic steatohepatitis…
HealthWell Foundation opens fund for MASH patients in US
The HealthWell Foundation, a charity that helps people who can’t afford to pay their medical bills, has started a new fund to support those…
US doctors prescribe Rezdiffra, note concern about patient costs
Physicians from the GI Alliance, the largest physician-led network of gastroenterologists in the U.S., are now actively prescribing Rezdiffra (resmetirom) to eligible people…
Namodenoson study for severe fatty liver disease cleared for US
Can-Fite BioPharma has been approved to enroll U.S. patients in its ongoing Phase 2b clinical trial of the oral treatment candidate namodenoson in people…
Intermittent fasting protects against fatty liver disease in mouse models
An intermittent fasting regimen reduced liver fat buildup and lowered the likelihood of liver cancer in mouse models of metabolic dysfunction-associated steatohepatitis (MASH), a severe…
GPR75 protein may be fatty liver disease therapeutic target: Study
Reduced activity of a protein called GPR75 appears to help prevent the buildup of fat in the liver and the subsequent development of metabolic dysfunction-associated…
Recent Posts
- US states, doctors split with CDC on hepatitis B shots for newborns
- PSC-IBD study shows need for regional management guidelines
- Staying on top of MASH may mean not staying on the transplant list
- Common virus may play a role in ICP development, study finds
- Lower-cost TAEUS device tracks liver fat on par with gold standard